D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
1. A pharmaceutical composition comprising at least one compound selected from the group consisting of:
2-amino-4-(2-chlorophenyl)butan-1-ol;
2-(3-aminohexyl)phenol;
4-(2-chlorophenyl)-butan-2-amine;
4-(2-chlorophenyl)-2-methylamino-butane;
4-(2-fluorophenyl)butan-2-amine;
4-(2-bromophenyl)butan-2-amine;
4-(2-iodophenyl)butan-2-amine;
4-(2-methoxyphenyl)butan-2-amine;
3-(3,4-diethoxyphenyl)propan-1-amine;
4-(4-chlorophenyl)butan-2-amine;
4-(4-methoxyphenyl)butan-2-amine;
any mixtures thereof; and any pharmaceutically acceptable salts thereof.
2. A compound selected from the group consisting of:
2-amino-4-(2-chlorophenyl)butan-1-ol;
2-(3-aminohexyl)phenol;
4-(2-iodophenyl)butan-2-amine;
4-(2-methoxyphenyl)butan-2-amine;
4-(4-chlorophenyl)butan-2-amine;
any mixtures thereof; and any pharmaceutically acceptable salts thereof.
3. A pharmaceutical composition comprising 4-(2-chlorophenyl)-butan-2-amine, or a pharmaceutically acceptable salt thereof.